Novo Holdings Announces Sale of KabaFusion

BOSTON, US, August 26, 2025 – Novo Holdings, a leading healthcare investment firm, announced that it has signed a definitive agreement to successfully exit its investment in KabaFusion (the “Company”). The transaction is subject to customary closing conditions.

Founded in 2010, KabaFusion is a leading U.S. provider of essential chronic and acute infusion therapies, serving patients in 45 states through its nationwide network of home infusion pharmacies, ambulatory infusion sites, and home health agencies.

Since partnering with Novo Holdings in November 2022, KabaFusion has meaningfully expanded its geographic footprint, enhanced its ambulatory infusion capabilities, and broadened its therapeutic offerings, all while maintaining the highest levels of clinical quality and the Company’s patient-first approach to care delivery.

Jonathan Levy, Senior Partner at Novo Holdings, said: “When we first invested in KabaFusion, we were impressed with their clinical leadership and patient-first approach. During our partnership, the Company has expanded its national presence and nearly doubled in size. We commend Founder and CEO Dr. Sohail Masood and the entire KabaFusion management team for their extraordinary work in executing the Company’s value creation plan and delivering such impressive growth, with patients at the center of everything they do.”

Abhijeet Lele, Senior Partner and Head of U.S. Principal Investments at Novo Holdings, added: “We have been delighted to be a part of KabaFusion’s growth trajectory and to have partnered with them on expansion initiatives to bring convenient and cost-effective therapy access to a broader array of patients. The Company has found a terrific new partner in Nautic Partners, and we wish the KabaFusion team continued success on their mission to deliver excellent patient care.”

KabaFusion Founder and CEO Dr. Sohail Masood said: “I am grateful for our current investor, Novo Holdings, whose partnership has been instrumental to our success. I also deeply appreciate the exceptional contributions of our talented team. As we enter this next chapter, we look forward to our new partnership and continuing to deliver on KabaFusion’s patient-first mission.”

Houlihan Lokey served as financial advisor, Goodwin Procter and Linklaters served as legal counsel, and Epstein Becker & Green served as regulatory counsel to KabaFusion.